A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
Status:
Completed
Trial end date:
2021-06-03
Target enrollment:
Participant gender:
Summary
Phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm
design study to evaluate the safety and duration of repeated IVT injections of 3 dose levels
of GB-102 compared with aflibercept.